We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Arecor Therapeutics Plc | LSE:AREC | London | Ordinary Share | GB00BMWLM973 | ORD GBP0.01 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -8.00 | -10.46% | 68.50 | 43,864 | 15:58:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 67.00 | 70.00 | 78.00 | 62.50 | 76.50 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Coml Physical, Biologcl Resh | 5.72M | -8.55M | -0.2266 | -3.02 | 28.88M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:41:06 | O | 25,000 | 67.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 02/12/2024 | 07:00 | UK RNS | Arecor Therapeutics PLC Grant of Options and PDMR Dealing |
| 18/11/2024 | 14:29 | ALNC |  IN BRIEF: Arecor Therapeutics names David Ellam as interim CFO |
| 18/11/2024 | 07:00 | UK RNS | Arecor Therapeutics PLC Arecor Appoints Interim Chief Financial Officer |
| 27/9/2024 | 06:00 | UK RNS | Arecor Therapeutics PLC Arecor to present on Investor Meet Company |
| 26/9/2024 | 18:33 | ALNC | EARNINGS: Hansard Global profit down; Flowtech cuts outlook |
| 26/9/2024 | 06:00 | UK RNS | Arecor Therapeutics PLC Interim Results for six months ended 30 June 2024 |
| 19/9/2024 | 14:17 | UK RNS | Arecor Therapeutics PLC Notice of Results |
| 11/9/2024 | 06:00 | UK RNS | Arecor Therapeutics PLC Arecor presents positive AT278 data at EASD |
| 03/9/2024 | 06:00 | UK RNS | Arecor Therapeutics PLC Arecor announces AT278 presentation at EASD 2024 |
| 22/8/2024 | 15:34 | UK RNS | Arecor Therapeutics PLC Holding(s) in Company |
Arecor Therapeutics (AREC) Share Charts1 Year Arecor Therapeutics Chart |
|
1 Month Arecor Therapeutics Chart |
Intraday Arecor Therapeutics Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 13/12/2024 | 14:12 | Arecor | 322 |
| 27/2/2024 | 09:01 | Current weakness | - |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2024-12-13 16:41:07 | 70.50 | 8,000 | 5,640.00 | O |
| 2024-12-13 16:20:38 | 69.85 | 216 | 150.88 | O |
| 2024-12-13 14:57:46 | 64.50 | 2,648 | 1,707.96 | O |
| 2024-12-13 13:54:51 | 65.00 | 1,000 | 650.00 | O |
| 2024-12-13 13:52:13 | 68.00 | 1,000 | 680.00 | O |
| Top Posts |
|---|
Posted at 14/12/2024 08:20 by Arecor Therapeutics Daily Update Arecor Therapeutics Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker AREC. The last closing price for Arecor Therapeutics was 76.50p.Arecor Therapeutics currently has 37,756,601 shares in issue. The market capitalisation of Arecor Therapeutics is £25,863,272. Arecor Therapeutics has a price to earnings ratio (PE ratio) of -3.02. This morning AREC shares opened at 76.50p |
Posted at 13/12/2024 14:12 by stupidboypike The share price decline continues and frankly it is difficult to see what would slow that down other than a cracking deal on a trial with the next AT278 trial. How they will get that when they are insisting on non-exclusive is beyond me. I am becoming increasingly frustrated at Arecor. If I had any sense I would probably get rid of half my holding, but it does appear that in the fullness of time it could come good, so I am hanging on. May well regret that!!!Best regards SBP |
Posted at 23/10/2024 08:54 by stupidboypike Jonesy,Yes I agree, despite my huge frustration over the share price and the way the financing/PR has been managed over the last few months, I do think Arecor is a winner. The technology clearly delivers something unique into a market worth many billions. I have a reasonable holding and don't plan on parting with any of them until a decent portion of that value comes out. A half decent deal on the next trial with AT278 could completely transform the market perception of Arecor. Here's hoping! Best regards SBP |
Posted at 16/10/2024 16:10 by stupidboypike The two "sells" of 9850 shares were a sale and purchase into my isa. (Nice to see the share price nudging up for once.)Best regards SBP |
Posted at 04/10/2024 01:55 by stupidboypike I worry that in hanging on for the very best deal, the share price will drop so low (even lower than now!!) and make us vulnerable to a cheap takeover.Best regards SBP |
Posted at 03/10/2024 14:08 by stupidboypike If anyone is on the webinar, I have just asked the following question:"What plans do the company have in light of the fact that the recent fund raise only raised enough cash for 24 months. As we have seen by the share price reaction, the market hates a company that is losing money and in constant need of funds. Is it hoped that a deal with AT278 will produce the long awaited "value inflexion point" that will shore up the cashflow within that 24 month window?" If anyone else is on the webinar and would like the answer please vote it up. Best regards SBP |
Posted at 24/9/2024 07:44 by jonesy100 There is an AREC results presentation being hosted by LSE on Thursday. Maybe we will find out then whether there is something badly wrong. |
Posted at 09/8/2024 08:01 by nchanning Like the tech here but as always on AIM the cash runway is still too tight ( 2 years optimistically) after the placing . What's going to happen in a year again ? The share price is going to tank fearing another discounted placing which will then cause big dilution to raise another meagre cash pile |
Posted at 10/6/2024 07:19 by stupidboypike I'm not one for conspiracy theories but you would swear this RNS was written to get the share price down, in summary:We are running out of cash, we don't know how to get more cash, we need a lot more cash (and time) to get interest in our biggest asset. This is either incompetence on a biblical scale or deliberate. As a long term patient shareholder I am not happy this morning. Best regards SBP |
Posted at 10/6/2024 07:19 by henley2 CEO showing that she has no clue as to how to run a listed company.It was obvious from the results that more money was required. She should have raised after the good news from AT278 trial. All today’s statement has done is crashed the share price, resulting in a lower price prior to the fundraising. |
Posted at 04/12/2023 13:16 by 127tolmers As foreshadowed in the TD report which calculated potential values of such a deal:Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces a co-development and exclusive licence option agreement with a leading global medical products company for a high-value, ready-to-dilute (“RTD”) oncology product from Arecor’s in-house Specialty Hospital pipeline. Under the terms of the agreement, Arecor and its partner will conduct further co-development and regulatory work with Arecor eligible to receive potential developmental milestones. The agreement includes an option for the partner to be granted an exclusive, worldwide license to further develop and commercialise the product, with Arecor eligible to receive milestones and royalty payments. Arecor has developed a proprietary RTD form of a lyophilized powder product using its formulation technology platform, Arestat™. This novel, liquid, RTD formulation of an existing ‘blockbuster&# |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
